Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
Particulars (in ₹ Cr.) | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
---|---|---|---|---|---|
Total Revenue | 308.72 | 252.92 | 196.01 | 143.95 | 132.88 |
Total Expenses | 254.24 | 201.32 | 157.53 | 118.61 | 108.15 |
Profit Before Tax | 54.48 | 51.60 | 38.48 | 25.34 | 24.73 |
Profit After Tax | 43.54 | 40.04 | 30.26 | 20.32 | 19.01 |
Operating Profit after Depreciation | 58.77 | 52.77 | 39.73 | 27.69 | 28.18 |
Particulars (in ₹ Cr.) | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
---|---|---|---|---|---|
Fixed Assets | 122.31 | 53.41 | 37.96 | 31.59 | 28.52 |
Total Non Current Assets | 196.33 | 106.93 | 46.28 | 37.07 | 32.18 |
Total Current Assets | 177.41 | 179.87 | 87.13 | 72.07 | 59.28 |
TOTAL ASSETS | 373.75 | 286.80 | 133.41 | 109.14 | 91.46 |
Total Shareholder's Fund | 268.36 | 227.78 | 94.20 | 64.59 | 44.88 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 12.89 | 29.02 | 5.85 | 29.55 | 12.14 |
Net Cash used in Investing Activities | -160.74 | -91.85 | -62.86 | -11.43 | -6.82 |
Net Cash used in Financing Activities | 172.10 | 26.21 | 108.37 | -10.69 | 3.14 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 329.07 | 297 | 252.03 | 191.20 | 143.71 |
Total Expenses | 273.94 | 245.42 | 203.07 | 154.08 | 118.26 |
Profit Before Tax | 55.14 | 51.58 | 48.97 | 37.12 | 25.45 |
Profit After Tax | 41.01 | 41.56 | 38.03 | 29.06 | 20.42 |
Operating Profit after Depreciation | 62.16 | 55.86 | 50.12 | 38.28 | 27.63 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 139.79 | 121.72 | 53.41 | 37.96 | 31.59 |
Total Non Current Assets | 360.92 | 197.44 | 107.06 | 46.41 | 37.20 |
Total Current Assets | 247.69 | 171.48 | 177.31 | 87.36 | 72.12 |
TOTAL ASSETS | 608.61 | 368.92 | 284.37 | 133.77 | 109.32 |
Total Shareholder's Fund | 410.26 | 265.57 | 227.18 | 94.89 | 66.56 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 15.05 | 27.68 | 5.35 | 27.90 | 11.93 |
Net Cash used in Investing Activities | -158.26 | -92.83 | -62.87 | -11.43 | -6.83 |
Net Cash used in Financing Activities | 162.72 | 26.28 | 108.38 | -8.82 | 3 |
Particulars (in ₹ Cr.) | 2024-12 | 2024-09 | 2024-06 | 2024-03 | 2023-12 |
---|---|---|---|---|---|
Total Revenue | 139.42 | 124.90 | 95.71 | 104.13 | 110.95 |
Total Expenses | 106.24 | 107.67 | 74.69 | 87.80 | 88.36 |
Profit Before Tax | 26.71 | 26.55 | 16.39 | 17.21 | 19.64 |
Profit After Tax | 20.51 | 21.02 | 12.76 | 15.17 | 16.11 |
Operating Profit after Depreciation | 35.20 | 31.87 | 22.70 | 23.57 | 24.30 |
Particulars (in ₹ Cr.) | 2024-12 | 2024-09 | 2024-06 | 2024-03 | 2023-12 |
---|---|---|---|---|---|
Total Revenue | 105.08 | 109.08 | 80.14 | 83.66 | 76.83 |
Total Expenses | 83.88 | 91.11 | 63.73 | 68.69 | 61.02 |
Profit Before Tax | 15.93 | 28.38 | 12.73 | 16.99 | 13.76 |
Profit After Tax | 9.68 | 21.72 | 9.29 | 11.73 | 10.77 |
Operating Profit after Depreciation | 23.25 | 32.55 | 18.09 | 22.14 | 17.49 |
₹0.1/Share
Company | Price | Market Cap (in ₹ Cr) |
---|---|---|
Sigachi Industries Ltd | ₹50.60 | ₹1,687.24 |
Sun Pharmaceuticals Industries Ltd | ₹1,761.80 | ₹4,22,714.84 |
Divis Laboratories Ltd | ₹5,818.40 | ₹1,54,460.24 |
Cipla Ltd | ₹1,427.30 | ₹1,15,270.75 |
Dr Reddys Laboratories Ltd | ₹1,288.45 | ₹1,07,511.36 |
Torrent Pharmaceuticals Ltd | ₹3,157.60 | ₹1,06,862.73 |
20 Jan 2025, 11:52 am
13 Jan 2025, 11:39 am
03 Jan 2025, 02:10 pm
29 Nov 2024, 12:20 pm
29 Nov 2024, 09:57 am